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Accurate identification of lymph node involvement is critical for successful treatment of patients with colorectal carcinoma (CRC).
Real-time quantitative RT–PCR with a specific probe and RNA copy standard for biomarker mRNA has proven very powerful for
detection of disseminated tumour cells. Which properties of biomarker mRNAs are important for identification of disseminated CRC
cells? Seven biomarker candidates, CEA, CEACAM1-S/L, CEACAM6, CEACAM7-1/2, MUC2, MMP7 and CK20, were compared in a
test-set of lymph nodes from 51 CRC patients (Dukes’ A–D) and 10 controls. Normal colon epithelial cells, primary tumours, and
different immune cells were also analysed. The biomarkers were ranked according to: (1) detection of haematoxylin/eosin positive
nodes, (2) detection of Dukes’ A and B patients, who developed metastases during a 54 months follow-up period and (3)
identification of patients with Dukes’ C and D tumours using the highest value of control nodes as cutoff. The following properties
appear to be of importance; (a) no expression in immune cells, (b) relatively high and constant expression in tumour tissue
irrespective of Dukes’ stage and (c) no or weak downregulation in tumours compared to normal tissue. CEA fulfilled these criteria
best, followed by CK20 and MUC2.
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It is now well established that the earlier the diagnosis of cancer,
the better the clinical outcome, through earlier administration of
effective and possibly curative treatments (Etzioni et al, 2003). For
colorectal cancer (CRC) the only curative treatment is surgery.
However, even after curative surgery the tumour recurs in many
instances. In CRC the prognostic predictor is tumour stage based
on histopathologic examination of the resected specimen com-
bined with perioperative findings (Dukes and Bussey, 1958;
Lindmark et al, 1994; Fleming et al, 1997). It has been shown
that adjuvant chemotherapy reduces the relative mortality rate by
one-third in patients operated for colon cancer in Dukes’ Stage C
(any TN1-2M0, Stage III) (Moertel et al, 1995; Fleming et al, 1997).
Adjuvant chemotherapy is not routinely given to patients of
Dukes’ Stage A (T1-2N0M0, Stage I) or Stage B (T3-4N0M0, Stage
II) although a substantial number of patients with Dukes’ Stage B
tumour will die from tumour recurrences. It is considered to be of
vital importance to improve the selection criteria in identifying
patients who may benefit from adjuvant chemotherapy and intense
follow-up protocols.
A key to these efforts is finding ways to specifically identify
disseminated tumour cells in regional lymph nodes. Different
techniques, for example analysis of multiple haematoxylin/eosin
(H&E)-stained sections, immunohistochemistry, gel-based quali-
tative reverse transcriptase–polymerase chain reaction (RT–PCR)
and more recently real-time quantitative RT–PCR (qRT–PCR),
and biomarkers including so-called surrogates of cancer have been
utilised (Tsavellas et al, 2001; Lotze et al, 2005). It can now be
concluded that real-time qRT–PCR assay for biomarker mRNA,
particularly when used with a specific probe and RNA copy
standard, is a superior method for micrometastases detection
because it is objective, highly sensitive and quantitative, and has a
very wide measuring range (Godfrey et al, 2001; Ho et al, 2004;
O ¨berg et al, 2004). Moreover, this technology lends itself to
automation and rapid test performance suitable for a clinical
setting (Raja et al, 2005).
In a recent study, we used real-time qRT–PCR for detection of
disseminated tumour cells in lymph nodes of CRC patients using
mRNA for two commonly used tumour markers, carcinoembryo-
nic antigen (CEA) and cytokeratin 20 (CK20) (O ¨berg et al, 2004).
The results were promising, particularly for CEA. However, there
might be biomarkers even more suitable for this purpose and
neither CEA nor CK20 discriminates between dislocated normal
intestinal epithelial cells (iECs) and tumour cells with propensity
to metastasize. Three kin molecules to CEA are expressed in the
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scolonic epithelium, that is CEA cell adhesion molecule-1
(CEACAM1), CEACAM6 and CEACAM7 (Horst and Wagener,
2004; Fra ¨ngsmyr et al, 1995, 1999). CEACAM6 has a wider cellular
distribution than CEA. However, it has been claimed that tumour
levels are higher for CEACAM6 than CEA and that CEACAM6
therefore would be the better tumour marker (Ilantzis et al, 2002;
Jantscheff et al, 2003). CEACAM1 comes with a long (CEACAM1-
L) or short (CEACAM1-S) cytoplasmic tail. The long cytoplasmic
tail of CEACAM1-L was shown to mediate tumour suppressor
function in model systems while the short cytoplasmic tail of
CEACAM1-S lacks this property (Hammarstro ¨m, 1999; Horst and
Wagener, 2004). Thus, CEACAM1-S might be a useful biomarker
and an increased CEACAM1-S/CEACAM1-L ratio an indicator of
tumour transformation. As far as one knows, CEACAM7 shows the
same restricted expression pattern as CEA. CEACAM7 mRNA
comes in two splice forms (CEACAM7-1 and CEACAM7-2) coding
for molecules that differ in the number of extracellular immuno-
globulin-like domains. Little is known about their relative
expression levels and possible changes in CRC. Mucin 2 (MUC2)
is the major mucin in colon (Weiss et al, 1996). It is a candidate
tumour marker since its expression is restricted to epithelial cells.
Finally, matrix metalloproteinase 7 (MMP7)/matrilysin is an
interesting candidate biomarker since it is expressed in the
invasive front of the primary tumour and MMP7 expression is
correlated with capacity to form metastases in CRC transfer
experiments (Adachi et al, 2001; Yamamoto et al, 2003).
The aims of this study were: (1) to determine which properties
of a tumour mRNA marker decide if it is suitable for detection of
tumour cells in tissues with an excess of immune cells, (2) to find
tumour markers that would be complementary to CEA mRNA by
improving sensitivity for the identification of disseminated tumour
cells in lymph nodes of CRC patients and (3) to find a biomarker
for tumour cells with metastasizing capacity.
MATERIALS AND METHODS
Patients
Surgery for CRC was carried out in 51 patients (32 men, 19 women;
median age 69 years, range 52–90). Thirty-five tumours were
located in colon and 16 in rectum. Seven patients with rectal
cancer received preoperative irradiation with 25Gy. Radical
excision of the tumours with wide lymph node dissection was
carried out in 42 patients. Nine patients had distant metastases.
Five patients received adjuvant chemotherapy. According to
Dukes’ classification there were six tumours in Stage A (T1-
2N0M0, Stage I), 26 in Stage B (T3-4N0M0, Stage II), 10 in Stage C
(anyTN1-2M0, Stage III) and nine in Stage D (anyTanyNM1, Stage
IV). At follow-up after median 54 months (range: 35–68) 19
patients had died from CRC and eight patients had died from
noncancer disease. None of the living patients had tumour
recurrence.
Controls included seven men and three women (median age 30
years, range: 18–61) undergoing colorectal surgery for ulcerative
colitis (UC; n¼6), Crohn’s disease (CD; n¼3) and rectal prolapse
(n¼1). Informed consent was obtained from the patients. The
local Research Ethics Committee of the Medical Faculty, Umea ˚
University, Sweden, approved our study.
Lymph nodes
One to four lymph nodes were dissected from surgically removed
specimens and bisected with separate knives under sterile
conditions to prevent RNA cross-contamination. One half of each
node was fixed in 10% buffered formalin for routine H&E staining
and the other half was snap frozen in liquid nitrogen and stored at
 701C until RNA extraction. In all, 95 lymph nodes were collected
from the CRC patients (11 nodes from Dukes’ Stage A patients, 55
nodes from Dukes’ Stage B patients, 16 nodes from Dukes’ Stage C
patients and 16 nodes from Dukes’ Stage D patients). In the control
group 18 nodes were from UC patients, 12 nodes from CD patients
and four nodes from the patient with rectal prolapse.
CRC tissue
An approximately 0.5 0.5 0.5cm piece was collected from the
outer rim of 20 tumour specimens immediately after resection (two
Dukes’ Stage A, 13 Dukes’ Stage B, two Dukes’ Stage C and three
Dukes’ Stage D), snap-frozen and kept at  701C until RNA
extraction.
Epithelial cells from colon tissue
Colonic epithelial cells were isolated from apparently normal tissue
constituting the resection margin after surgical removal of tumour
in CRC patients and from colon of UC patients subjected to
surgical treatment as described earlier (Fahlgren et al, 2003b). The
isolation procedure yields one fraction enriched in crypt epithelial
cells (crypt-iECs) and one fraction enriched in luminal epithelial
cells (luminal-iECs).
Cell lines and peripheral blood mononuclear cells
Human cell lines used were: LS174T, T84, HT29, and HCT8 (colon
carcinomas), Jurkat and Molt-4 (T-cell lymphomas), CNB6 and
KR4 (EBV-transformed B cell lines; a mixture of equal amounts of
RNA from the two lines was used in the analyses), U266
(plasmacytoma), U937 (monocyte-like cell line), K562 (erythro-
blastoid cell line), HL60 (promyelocytic cell line). Peripheral blood
mononuclear cells (PBMC) were isolated from peripheral blood of
healthy adults by Ficoll-Isopaque gradient centrifugation. PBMC
were in vitro activated by incubation with anti-CD3 mAb OKT3
(50ngml
 1) in HEPES-buffered RPMI1640 supplemented with
0.4% human serum albumin. PBMC from seven individuals were
incubated with the stimulus in parallel cultures for 4, 7, 20, 48 and
72h, washed, pooled and RNA extracted.
RNA extraction
Total RNA was extracted using the Acid Guanidine Phenol
Chloroform (AGPC) method by adding 0.5ml of a solution
containing 4 M guanidinium thiocyanate, 25mM sodium citrate
(pH 7), 0.5% sarcosyl and 0.1 M 2-mercaptoethanol per 25mg
tissue and up to 2.5 10
6 cells in the first homogenization step.
Extracted RNA was dissolved in RNAse-free water containing
RNAse inhibitor.
Real-time qRT–PCR
Real-time qRT–PCR assays for CEA, CEACAM6, CEACAM1-S,
CEACAM1-L, CEACAM7-1, CEACAM7-2, MUC2, MMP7 and CK20
mRNAs were constructed in the laboratory using the TaqMan EZ
technology (Applied Biosystems, Foster City, CA, USA). Specific
primer pairs were placed in different exons and a dye-labelled
probe was placed over the boundary between the two exons in the
amplicon. Assays for all markers except MMP7 have been
described (Fahlgren et al, 2003a; Forsberg et al, 2004; O ¨berg
et al, 2004). The sequences for the MMP7 primers and probe were:
forward primer 50-GGGAGGCATGAGTGAGCTAC-30, reverse
primer 50-TCTCCTTGAGTTTGGCTTCTAAA-30 and probe 50-
TCTTGAGATAGTCCTGAGCCTGTTCCCA-30. The reporter dye at
the 50-end of each probe was FAM. The quencher dye at the 30-end
was TAMRA for CEA, CEACAM1-L, CEACAM6, CEACAM7-2,
CK20 and MMP7, and MGB for CEACAM1-S, CEACAM7-1 and
MUC2. Emission from released reporter dye was monitored by the
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sABI Prism 7700 Sequence Detection System (Perkin-Elmer, Well-
esley, MA, USA). The RT–PCR profile for all assays except
CEACAM7-1 was: 491C for 2min, 591C for 30min, 941C for 5min
followed by 45 cycles of 931C for 20s and 611C for 1min. The RT–
PCR profile for CEACAM7-1 was: 491C for 2min, 591C for 30min,
941C for 5min followed by 45 cycles of 931C for 20s and 591C for
1min. Specific RNA copy standards were prepared as described
previously (Fahlgren et al, 2003b). Determinations were carried
out in triplicates and expressed as copies of mRNA per mla s
determined from parallel RT–PCR of serial dilutions of the RNA
copy standard. The concentration of 18S rRNA was determined in
each sample by real-time qRT–PCR according to the manufac-
turer’s protocol (Applied Biosystems). As no copy standard is
available for the 18S rRNA assay the 18S rRNA content was
expressed as arbitrary units defined as the amount of 18S rRNA in
1pg total RNA extracted from PBMC. Results are expressed as
mRNA copies per unit of 18S rRNA.
Statistics
The mRNA expression levels in iECs of normal and inflamed colon
were compared using two-tailed Mann–Whitney’s rank sum test.
Comparisons between mRNA expression levels in tumour vs
normal iECs and between levels of different mRNA species in
tumour tissue were performed using Kruskal–Wallis’ nonpara-
metric one-way ANOVA with Dunn’s multiple comparison post
hoc test. Analyses of correlations between levels of different mRNA
species were performed using two-tailed Spearman rank correla-
tion test. A P-value o0.05 was considered statistically significant.
RESULTS
Biomarker mRNA levels in colonic epithelial cells and CRC
tumours
Levels of CEA, CEACAM1-S/L, CEACAM6, CEACAM7-1/2, MUC2,
MMP7 and CK20 mRNAs were assessed in RNA extracted from
primary tumours representing all four Dukes’ stages and from
luminal-iECs and crypt-iECs of apparently normal and inflamma-
tory colon using specific real-time qRT–PCR assays with RNA
copy standards. The 18S rRNA concentration was determined in
each sample and levels are expressed as mRNA copies/18S rRNA
unit allowing direct comparison between the different biomarkers.
Statistically significant difference in mRNA levels between iECs
from normal and inflammatory colon was only seen for MMP7 (see
legend to Table 1), therefore the two groups were combined in the
comparisons against tumour tissue. Table 1 summarises the
results. The mRNA levels of the different biomarkers varied
considerably within the tumours, from median 107 mRNA copies/
18S rRNA unit for CEA to 0.05 for CEACAM7-1. CEA and
CEACAM6 mRNAs were expressed at approximately equal levels in
tumours and iECs while the mRNA levels for CEACAM7-1/2,
CEACAM1-L, MUC2 and CK20 were significantly decreased in the
tumour. Only MMP7 mRNA levels were increased in the tumour
compared to iECs (Table 1). Table 2 shows the mRNA levels of the
biomarkers in four CRC cell lines. Among the biomarkers CEA
exhibited the highest expression level and smallest variation
between CRC cell lines.
Biomarker mRNA levels in immune cells
Table 2 summarises the results of analysis of polyclonally activated
and resting PBMC and seven immune cell lines. Four biomarker
mRNAs were not detected or were detected in trace amounts only
in one type of immune cells. These were MUC2, CEA, CEACAM7-2
and CK20. Other biomarkers were expressed at high levels in one
or several types of immune cells (CEACAM1-L, CEACAM6,
MMP7) or at low levels (CEACAM1-S, CEACAM7-1).
Specificity indexes
To rank the different biomarkers with respect to specificity for
CRC we calculated two types of specificity indexes: (I) median
value in CRC tumours/highest value in any type of immune cell
and (II) median value in CRC tumours/highest value of control
lymph nodes (Table 3). As can be seen, the two indexes gave
similar values with the exceptions of those for CEACAM6 and
CEACAM7-2. CEA was the most specific biomarker followed by
CK20. CEACAM6 showed better specificity with index II than
index I, while the reverse was true for CEACAM7-2. Indexes for
three biomarkers (CEACAM1-L, CEACAM7-1, MMP7) showed no
specificity for CRC.
Biomarker mRNA levels in lymph nodes of CRC patients
and controls
A total of 129 lymph nodes of 51 CRC patients and 10 controls
were analysed for mRNA levels of the biomarkers. Figures 1–3
summarise the results. For each individual only the lymph node
Table 1 Expression levels of mRNAs for CEA, CEACAM1, CEACAM6, CEACAM7, MUC2, MMP7, and CK20 in primary colorectal tumours compared
to control colonic epithelial cells
Tumour Crypt iEC
a Luminal iEC
mRNA species Median
b IQR
c Median IQR P-value
d Median IQR P-value
CEA 107 39–1207 261 225–537 NS 393 212–769 NS
CEACAM6 20 6.5–55 28 14–35 NS 38 13–116 NS
CEACAM1-S 5.1 2.5–14 19 12–34 o0.01 28 12–72 o0.01
CEACAM1-L 1.4 0.43–6.4 16 8.0–40 o0.001 22 10–40 o0.001
CEACAM7-1 0.05 0.005–0.37 0.90 0.67–2.9 o0.001 1.9 1.2–6.0 o0.001
CEACAM7-2 9.0 0.94–32 302 162–468 o0.001 483 361–582 o0.001
MUC2 0.66 0.04–3.4 32 25–56 o0.001 33 17–77 o0.001
MMP7 1.7 0.85–4.3 0.09 0.01–0.25 o0.01 0.09 0.003–16 o0.05
CK20 14 5.5–40 295 178–675 o0.001 162 104–377 o0.001
aiEC¼intestinal epithelial cells.
bMedian mRNA copies/18S rRNA unit of 20 CRC tumour samples (2 Dukes’ Stage A, 13 Dukes’ Stage B, 2 Dukes’ Stage C and 3 Dukes’ Stage
D), 14–20 crypt iEC samples and 10–20 luminal iEC samples. Equal numbers of iEC samples were derived from the apparently healthy resection margin of colon from patients
operated for CRC and from colon of UC patients. The mRNA expression levels for any of the markers in iEC from normal colon of CRC patients and UC colon, respectively, did
not differ significantly from each other with the exception of MMP7 mRNA. MMP7 mRNA levels were significantly higher (Po0.01) in the iECs from UC patients compared to
iEC from the resection margin of CRC patients. MMP7 values for iEC in the Table include data from 10 CRC and 10 UC patients.
cIQR¼interquartile range from the 25 to the
75 percentile.
dP-value obtained by comparing mRNA expression levels in tumours with those in crypt iECs, and luminal iECs using Kruskal–Wallis nonparametric one-way
ANOVA with Dunn’s multiple comparison post hoc test. NS¼not significant, that is P-value 40.05.
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swith the highest level of the indicated mRNA species is shown. For
each biomarker, a cutoff level is set at the highest control node.
CEA mRNA showed excellent discrimination between nodes
from CRC patients and controls (Figure 1). Practically all CRC
nodes were above the cutoff level independent of Dukes’ Stage and
all H&E positive lymph nodes had very high CEA mRNA levels.
Moreover, the three Dukes’ B patients that have died from their
CRC within the 54 months follow-up period displayed highly
elevated CEA mRNA levels (arrows in figure). The single Dukes’ A
patient that has died from her CRC showed a borderline value
(arrow).
CEACAM1-S mRNA (Figure 2A) showed some discrimination
between CRC and controls. Nodes of 1/6 Dukes’ A, 5/24 Dukes’ B,
7/10 Dukes’ C and 2/8 Dukes’ D patients were above cutoff and all
but one H&E positive nodes were identified as positive by
CEACAM1-S mRNA level. Moreover, two of the three Dukes’ B
patients, but not the Dukes’ A patient, that have died from their
CRC within the follow-up period were identified. Note also that the
total range of values is much smaller for CEACAM1-S than for
CEA, that is four and seven orders of magnitude, respectively, and
that the CEACAM1-S levels in controls are almost 100 times
higher.
No discrimination between CRC and control nodes was seen
with CEACAM1-L mRNA (Figure 2B). The CEACAM1-L mRNA
levels of control nodes were very high, which is consistent with the
high levels of CEACAM1-L mRNA in immune cells (Table 2).
CEACAM7-1 mRNA was not a useful marker (Figure 2C) while
CEACAM7-2 mRNA, which was expressed at about 100 times
higher concentration, displayed some discriminating power
between CRC patients and controls (Figure 2D). However, several
H&E positive nodes were missed and one of the three Dukes’ B
patients and the Dukes’ A patient that have died from CRC within
the follow-up period were missed.
MUC2 mRNA showed good discrimination between CRC nodes
and control nodes comparable to that of CEA mRNA. All but one
of the H&E positive nodes and all three Dukes’ B patients who
had died from CRC had values above the cutoff (Figure 3A).
Interestingly, MUC2 mRNA values are very low in controls and the
range of values in CRC is quite large.
Similarly, CK20 mRNA showed good discrimination between
nodes from CRC patients and controls (Figure 3B). All H&E
positive nodes as well as the three Dukes’ B patients who have died
Table 2 Expression levels of mRNA for CEA, CEACAM1, CEACAM6, CEACAM7, MUC2, MMP7, and CK20 in CRC cell lines and different types of
immune cells
Biomarker mRNA
Cells Origin CEA CEACAM6 CEACAM1-S CEACAM1-L CEACAM7-1 CEACAM7-2 MUC2 MMP7 CK20
HT29 Colon iEC 32
a 43 22 17 0.003 0.3 0.01 53 85
LS174T Colon iEC 328 81 1.2 1.4 0.5 38 4.3 3.4 0.02
T84 Colon iEC 33 1.0 0.9 0
b 0.003 0.07 0.5 2.3 33
HCT8 Colon iEC 32 0.5 0.003 0 0 0.1 0.02 0.2 0.05
PBMC 0 0.05 0 0.3 0.01 0 0 0.001 0
Act. PBMC 0 0 0.001 0.8 0 0 0 2.0 0
Jurkat T cell 0 0 0.004 0.1 0 0 0 0.004 0
Molt-4 T cell 0 0 0.002 0.05 0 0 0 0 0
CNB6+KR4 B cell 0 0 0.008 1.1 0.05 0 0 0.6 0
U266 Plasma cell 0 0 0.001 0.02 0 0 0 0 0
U937 Monocyte 0.005 0.3 0.002 0.03 0 0 0 0.9 0.003
HL60 Granulocyte 0 1.8 0 ND 0 0.001 ND 0 0
K562 Pre-erythrocyte 0 0 0.006 0.08 0 0 0 0 ND
aExpression level of the indicated mRNA species expressed as mRNA copies/18S rRNA unit.
bValues below 0.001 mRNA copies/18S rRNA unit are recorded as 0. ND¼not
determined.
Table 3 Specificity indexes for tumour marker mRNAs
mRNA species
Median CRC tumour
value/highest value of
any immune cell type
Median CRC tumour
value/highest value of
control lymph nodes
CEA 21400 53500
CEACAM6 11 2000
CEACAM1-S 638 39
CEACAM1-L 1.3 0.4
CEACAM7-1 1.0 6.3
CEACAM7-2 9000 90
MUC2 4660 942
MMP7 0.9 1.1
CK20 4667 15555
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Figure 1 CEA mRNA levels in lymph nodes as determined by real-time
qRT–PCR for CEA mRNA and 18S rRNA content in the samples. Each
patient is represented by the lymph node with the highest CEA mRNA
level (dots). Arrows indicate the four patients with Dukes’ Stage A and B
tumours, who had died from CRC during the 54 months (range: 35–68
months) follow-up time. Large black dots indicate lymph nodes that had
tumour cells identified by H&E staining and small grey dots indicate H&E
negative nodes. Results updated from O ¨ berg et al, 2004.
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sfrom CRC during the follow-up period were identified as positive.
CK20 mRNA levels in CRC nodes varied over a wide range and
control nodes were low.
CEACAM6 mRNA displayed fairly good ability to discriminate
between CRC patients and controls (Figure 3C). However, only two
of the three Dukes’ B patients that have died from their CRC within
the follow-up period had elevated CEACAM6 levels. All H&E
positive nodes displayed CEACAM6 mRNA levels above cutoff.
MMP7 mRNA displayed poor discriminating power between
CRC patients and controls (Figure 3D).
Correlation between different biomarker mRNA levels in
lymph nodes of CRC patients and controls
The four biomarker mRNAs which showed the best discriminating
power between CRC and control nodes and which were not
appreciably expressed in immune cells namely CEA, CEACAM7-2,
CK20 and MUC2 were analysed by pair-wise comparisons of
biomarker levels in all 129 lymph nodes. Each Dukes’ Stage and
controls were also analysed separately. Table 4 shows correlation
coefficients (r-values) and significance levels (P-values) for all six
comparisons. Biomarker mRNA values were significantly corre-
lated if all nodes were compared with r-values ranging from 0.47 to
0.76. When the different stages of CRC were analysed separately it
was noted that lymph nodes from Dukes’ C and Dukes’ D patients
showed r-valuesX0.5 and P-valuesp0.05 for all marker combina-
tions except one indicating that it was the same cells that expressed
the four markers. The comparisons furthermore demonstrate that
CEACAM7-2 is also expressed in a separate cell population
normally present in lymph nodes. The results also indicate that
control nodes harbour low numbers of two cell populations of
epithelial origin, one expressing CEA, CK20 and CEACAM7-2 and
another expressing MUC2, CK20 and CEACAM7-2.
DISCUSSION
In this study, we have explored the possibility of using real-time
qRT–PCR as an alternative, or adjunct, to the classical H&E
staining method for detection of disseminated tumour cells in
regional lymph nodes. There are several reasons to search for
alternatives. Firstly an inherent problem with histochemical as well
as immunohistochemical methods is that of sampling. Usually,
only one or a few 6mm thick sections are analysed covering o1%
of the lymph node volume. To analyse the number of sections that
would be needed to properly cover the node becomes impossible in
practice. In the qRT–PCR study reported here, we extracted RNA
from one half of the lymph node. A second problem specific for
H&E is to decide on the basis of morphology alone whether a small
number of cells indeed are tumour cells. Thirdly, and in contrast
to H&E and immunohistochemistry, the qRT–PCR assay is very
sensitive and objective and has a very large measuring range. With
the appropriate choice of primers and probes, it can be made
highly specific for the chosen marker mRNA. Moreover, since
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Figure 2 CEACAM1-S (A), CEACAM1-L (B), CEACAM7-1 (C), and CEACAM7-2 (D) mRNA levels in lymph nodes of CRC and control patients. Each
patient is represented by the lymph node with the highest level of the respective mRNA species. For explanation of dots and arrows see legend to Figure 1.
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level positive results are likely to reflect the presence of living
tumour cells. It has been shown that dendritic cells/macrophages
can transport protein components from apoptotic epithelial cells
to lymph nodes (Bonnotte et al, 2000; Huang et al, 2000). A yet
unresolved question in using qRT–PCR for the purpose of
detecting disseminated tumour cells in regional lymph nodes is,
however, which biomarker mRNA to use.
A major goal of this study was to determine which properties of
a tumour marker mRNA are of importance for the detection
of disseminated colon tumour cells in the presence of an excess of
immune cells for example in regional lymph nodes and blood. We,
therefore, investigated a number of biomarkers, that are expressed
in colon adenocarcinoma cells and compared their expression
levels in a test-set of lymph nodes from CRC patients of different
Dukes’ stages and controls as well as in primary tumours, in
epithelial cells of normal and inflamed colon and in different types
of immune cells.
We found that CEACAM1-S/L, CEACAM7-1/2, MUC2 and CK20
mRNAs were expressed at lower levels in the primary tumour
compared to normal colon. CEACAM1 and CEACAM7 mRNAs
have previously been shown to be downregulated in CRC using
semiquantitative methods (Neumaier et al, 1993; Nollau et al,
1997). In contrast, neither CEA nor CEACAM6 mRNA levels were
B
D
A
M
U
C
2
 
m
R
N
A
 
c
o
p
i
e
s
/
1
8
S
 
r
R
N
A
 
u
n
i
t
C
K
2
0
 
m
R
N
A
 
c
o
p
i
e
s
/
1
8
S
 
r
R
N
A
 
u
n
i
t
C
C
E
A
C
A
M
6
 
m
R
N
A
 
c
o
p
i
e
s
/
1
8
S
 
r
R
N
A
 
u
n
i
t
10–6
10–5
10–4
10–3
10–2
10–1
100
101
102
103
10–6
10–5
10–4
10–3
10–2
10–1
100
101
102
103
10–6
10–5
10–4
10–3
10–2
10–1
100
101
102
103
10–6
10–5
10–4
10–3
10–2
10–1
100
101
102
103
M
M
P
7
 
m
R
N
A
 
c
o
p
i
e
s
/
1
8
S
 
r
R
N
A
 
u
n
i
t
Ctr Dukes' A Dukes' B Dukes' C Dukes' D Ctr Dukes' A Dukes' B Dukes' C Dukes' D
Ctr Dukes' A Dukes' B Dukes' C Dukes' D Ctr Dukes' A Dukes' B Dukes' C Dukes' D
Figure 3 MUC2 (A), CK20 (B), CEACAM6 (C), and MMP7 (D) mRNA levels in lymph nodes of CRC and control patients. Each patient is represented
by the lymph node with the highest level of the respective mRNA species. For explanation of dots and arrows see legend to Figure 1.
Table 4 Correlation between expression levels of biomarker CEA, CEACAM7-2, CK20 and MUC2 mRNAs in lymph nodes of CRC patients and controls
All lymph nodes Controls Dukes’ A Dukes’ B Dukes’ C Dukes’ D
Compared mRNA species r
a P-value
a rP -value rP -value rP -value rP -value rP -value
CEA vs CK20 0.76 o0.0001 0.47 0.005 0.80 0.005 0.58 o0.0001 0.70 0.004 0.76 0.0006
MUC2 vs CK20 0.62 o0.0001 0.50 0.004 0.62 0.04 0.45 0.001 0.69 0.007 0.60 0.05
CEA vs MUC2 0.71 o0.0001 0.33 NS 0.60 NS 0.55 o0.0001 0.78 0.0006 0.80 0.003
CEA vs CEACAM7-2 0.62 o0.0001 0.64 o0.0001 0.42 NS 0.40 0.004 0.54 0.03 0.89 0.0003
CEACAM7-2 vs CK20 0.47 o0.0001 0.53 0.001 0.37 NS 0.16 NS 0.52 0.05 0.85 0.002
CEACAM7-2 vs MUC2 0.55 o0.0001 0.43 0.02 0.44 NS 0.43 0.003 0.41 NS 0.80 0.005
ar- and P-values obtained by pair-wise comparing the expression levels of the indicated mRNA species in lymph nodes of CRC patients and controls using two-tailed Spearman
rank correlation test. Numbers of lymph nodes in the analysis were 120–129 for all lymph nodes, 33–34 for controls, 10–11 for Dukes’ A patients, 48–52 for Dukes’ B patients,
15–16 for Dukes’ C patients and 12–16 for Dukes’ D patients. NS¼not significant, P-value40.05.
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sdecreased in tumour tissue. MMP7 was the only marker that
exhibited increased levels in tumours. However, the levels were
still low compared to CEA. CEA and CEACAM1-S levels displayed
the smallest variation between individual primary tumour tissue
samples and there was no tendency for changes in relation to
Dukes’ stages for these two markers. Of all biomarkers CEA mRNA
was expressed at the highest levels in tumours followed by
CEACAM6. The high levels of these two markers could possibly be
explained by the fact that CEA and CEACAM6 are expressed both
in columnar epithelial cells and goblet cells in normal colon while
CEACAM1 and CEACAM7 are expressed in columnar epithelial
cells only and MUC2 in goblet cells only (Weiss et al, 1996;
Fra ¨ngsmyr et al, 1999).
It can be argued that no or only marginal expression of the
biomarker in immune cells should be of utmost importance for
successful detection of tumour cells in lymph nodes. Indeed, three
of the four biomarkers that were expressed in only trace amounts
in immune cells, that is CEA, CK20 and MUC2, showed good
discriminatory capacity between nodes from CRC patients and
controls. Owing to its low expression in immune cells one would
have predicted excellent discriminatory capacity also by CEA-
CAM7-2 but this was not the case. Possibly CEACAM7-2 is
expressed in some additional cell type in lymph nodes, for example
endothelial cells or stromal cells.
CEA mRNA showed excellent separation between CRC patients
and controls. MUC2 and CK20 mRNAs had almost the same
discriminating power as CEA mRNA. The Dukes’ B patients who
developed metastatic disease during the follow-up period were all
detected by the three markers but only for CEA were all Dukes’ C
nodes above the cutoff value. Moreover, one H&E positive lymph
node was missed by the MUC2 mRNA assay.
It was somewhat unexpected that MUC2 gave essentially the
same result as CEA although in normal colon MUC2 is confined to
goblet cells and not expressed in columnar epithelial cells. Does all
CRC tumour disseminated to the lymph node contain goblet cell-
like elements? We do not know whether this is the case. Possibly
MUC2 expression can be induced by external agents in CRC
tumour cells. It was recently shown that bile acids induce MUC2
overexpression in human colon carcinoma cells (Song et al, 2005).
Furthermore, we found that the inflammatory state of the small
intestinal mucosa in patients with active celiac disease is associated
with ectopic production of MUC2 by enterocytes (Forsberg et al,
2004). Thus, the cytokine milieu in the nodes might upregulate
MUC2 expression in the iECs.
Although CEA and CEACAM6 behaved very similar CEA had a
higher discriminatory power. This was due to CEA that, contrary
to expectation, had higher expression level in tumour cells than
CEACAM6 and that CEACAM6 was expressed in myeloid immune
cells with the risk that tumour cells expressing fairly low levels of
this marker would drown in the immune cell background of the
node.
The two markers for tumour cell ‘aggressiveness’ studied here,
that is MMP7 and CEACAM1-S, were not suitable for analysis of
lymph nodes. MMP7 because its expression was induced in
activated T lymphocytes, a cell type which is likely to be prominent
in lymph nodes. CEACAM1-S was not suitable because (1) it was
expressed in several types of immune cells although at low levels
and (2) the very high expression level of CEACAM1-L in immune
cells precludes meaningful calculation of CEACAM1-S: CEACAM1-L
ratios in lymph nodes.
In conclusion, the finding that three independent biomarker
mRNAs, CEA, MUC2 and CK20, gave almost the same results
with highly selective expression in cells of epithelial origin
strongly support the notion that disseminated tumour cells
can be successfully detected in regional lymph nodes by this
technique. CEA mRNA appears to be the best choice as single
marker due to its remarkably high expression level in colorectal
tumour cells.
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